Literature DB >> 19180099

Trial watch: Phase III promise for oral multiple sclerosis therapy.

.   

Abstract

Mesh：

Substances：

Year:  2009        PMID： 19180099     DOI： 10.1038/nrd2821

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  2 in total

Review 1.  Novel therapeutic strategies for multiple sclerosis--a multifaceted adversary.

Authors:  Rocio S Lopez-Diego; Howard L Weiner
Journal:  Nat Rev Drug Discov       Date:  2008-11       Impact factor: 84.694

Review 2.  FTY720, a new class of immunomodulator, inhibits lymphocyte egress from secondary lymphoid tissues and thymus by agonistic activity at sphingosine 1-phosphate receptors.

Authors:  Kenji Chiba
Journal:  Pharmacol Ther       Date:  2005-06-13       Impact factor: 12.310
  2 in total
  2 in total

1.  Does fingolimod in multiple sclerosis patients cause macular edema?

Authors:  Kiran Turaka; Joseph Shepard Bryan
Journal:  J Neurol       Date:  2012-01-10       Impact factor: 4.849

Review 2.  Opening the flood-gates: how neutrophil-endothelial interactions regulate permeability.

Authors:  Matthew R DiStasi; Klaus Ley
Journal:  Trends Immunol       Date:  2009-09-23       Impact factor: 16.687
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.